Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
ApprovedCompletedDevelopment Stage
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Nov 1, 1996 → Nov 1, 2004
About Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) is a approved stage product being developed by Mochida Pharmaceutical for Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00231738. Target conditions include Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00231738 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease